BioMarin cuts staff along with sales projections

Generic competition has cut deeply into the sales of the child asthma drug Orapred, forcing BioMarin to cut its sales projections and hand pink slips to 52 members of its sales force. The sales forecast for the drug was cut to $8 million to $10 million, from $15 million to $20 million. "In the last several weeks generic competition to Orapred has intensified and the Orapred market share has continued to erode," the Swiss company's CEO, Jean-Jacques Bienaime, said in a statement.

- read this article from the San Francisco Business Times for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.